Show simple item record

dc.contributor.advisorJoaquim Bellmunt, Judith A. Savageau
dc.contributor.authorMartin-Doyle, William
dc.contributor.authorLeow, Jeffrey J.
dc.contributor.authorOrsola, Anna
dc.contributor.authorChang, Steven L.
dc.contributor.authorBellmunt, Joaquim
dc.date2022-08-11T08:10:55.000
dc.date.accessioned2022-08-23T17:24:36Z
dc.date.available2022-08-23T17:24:36Z
dc.date.issued2015-01-05
dc.date.submitted2015-02-09
dc.identifier.citationJ Clin Oncol. 2015 Jan 5. [Epub ahead of print] doi: 10.1200/JCO.2014.57.6967.
dc.identifier.issn1527-7755
dc.identifier.doi10.1200/JCO.2014.57.6967
dc.identifier.pmid25559810
dc.identifier.urihttp://hdl.handle.net/20.500.14038/49226
dc.description<p>Medical student William Martin-Doyle participated in this study as part of the Senior Scholars research program at the University of Massachusetts Medical School.</p>
dc.description.abstractPURPOSE: High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable prognosis, poorly understood risk factors, and considerable debate about the role of early cystectomy. We aimed to address these questions through a meta-analysis of outcomes and prognostic factors. METHODS: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and American Society of Clinical Oncology abstracts were searched for cohort studies in HGT1. We pooled data on recurrence, progression, and cancer-specific survival from 73 studies. RESULTS: Five-year rates of recurrence, progression, and cancer-specific survival were 42% (95% CI, 39% to 45%), 21% (95% CI, 18% to 23%), and 87% (95% CI, 85% to 89%), respectively (56 studies, n = 15,215). In the prognostic factor meta-analysis (33 studies, n = 8,880), the highest impact risk factor was depth of invasion (T1b/c) into lamina propria (progression: hazard ratio [HR], 3.34; P < .001; cancer-specific survival: HR, 2.02; P = .001). Several other previously proposed factors also predicted progression and cancer-specific survival (lymphovascular invasion, associated carcinoma in situ, nonuse of bacillus Calmette-Guérin, tumor size > 3 cm, and older age; HRs for progression between 1.32 and 2.88, P ≤ .002; HRs for cancer-specific survival between 1.28 and 2.08, P ≤ .02). CONCLUSION: In this large analysis of outcomes and prognostic factors in HGT1 bladder cancer, deep lamina propria invasion had the largest negative impact, and other previously proposed prognostic factors were also confirmed. These factors should be used for prognostication and patient stratification in future clinical trials, and depth of invasion should be considered for inclusion in TNM staging criteria. This meta-analysis can also help define selection criteria for early cystectomy in HGT1 bladder cancer, particularly for patients with deep lamina propria invasion combined with other risk factors.
dc.language.isoen_US
dc.publisherAmerican Society of Clinical Oncology
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25559810&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1200/JCO.2014.57.6967
dc.subjectDiagnosis
dc.subjectHealth Services Research
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectSurgical Procedures, Operative
dc.subjectUrology
dc.titleImproving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients
dc.typeJournal Article
dc.source.journaltitleJournal of clinical oncology : official journal of the American Society of Clinical Oncology
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/ssp/162
dc.identifier.contextkey6628321
html.description.abstract<p>PURPOSE: High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable prognosis, poorly understood risk factors, and considerable debate about the role of early cystectomy. We aimed to address these questions through a meta-analysis of outcomes and prognostic factors.</p> <p>METHODS: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and American Society of Clinical Oncology abstracts were searched for cohort studies in HGT1. We pooled data on recurrence, progression, and cancer-specific survival from 73 studies.</p> <p>RESULTS: Five-year rates of recurrence, progression, and cancer-specific survival were 42% (95% CI, 39% to 45%), 21% (95% CI, 18% to 23%), and 87% (95% CI, 85% to 89%), respectively (56 studies, n = 15,215). In the prognostic factor meta-analysis (33 studies, n = 8,880), the highest impact risk factor was depth of invasion (T1b/c) into lamina propria (progression: hazard ratio [HR], 3.34; P < .001; cancer-specific survival: HR, 2.02; P = .001). Several other previously proposed factors also predicted progression and cancer-specific survival (lymphovascular invasion, associated carcinoma in situ, nonuse of bacillus Calmette-Guérin, tumor size > 3 cm, and older age; HRs for progression between 1.32 and 2.88, P ≤ .002; HRs for cancer-specific survival between 1.28 and 2.08, P ≤ .02).</p> <p>CONCLUSION: In this large analysis of outcomes and prognostic factors in HGT1 bladder cancer, deep lamina propria invasion had the largest negative impact, and other previously proposed prognostic factors were also confirmed. These factors should be used for prognostication and patient stratification in future clinical trials, and depth of invasion should be considered for inclusion in TNM staging criteria. This meta-analysis can also help define selection criteria for early cystectomy in HGT1 bladder cancer, particularly for patients with deep lamina propria invasion combined with other risk factors.</p>
dc.identifier.submissionpathssp/162
dc.contributor.departmentSchool of Medicine
dc.contributor.studentWilliam Martin-Doyle


This item appears in the following Collection(s)

Show simple item record